Compare Moderna, Inc. (MRNA) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs OneSpan Inc — how do they compare? Moderna, Inc. trades at $135.89 (market cap $56.02B), while OneSpan Inc trades at $16.12 (market cap $593.32M). The key difference: Moderna, Inc. is far larger — about 94.4× OneSpan Inc's market cap, and OneSpan Inc pays a 3.23% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | OSPN | |
|---|---|---|
Market Cap | $56.02B | $593.32M |
Sector | Health | Technology |
52-Week High | $174.38 | $16.92 |
52-Week Low | $22.36 | $10.15 |
Enterprise Value | $52.17B | $562.40M |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
OneSpan (OSPN) trades at $16.1, down 3.59% on the day, with technical indicators showing a neutral trend and key support at $16. The stock exhibits strong fundamentals, including a P/E of 9.1, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights institutional interest, such as Deutsche Bank's new position, and the company's introduction of DigipassONE for authentication modernization.
The outlook for OSPN is positive, supported by solid financials and analyst consensus, but risks include competitive pressures and cash flow volatility. With a consensus price target of $17.00 and 66.67% buy ratings, the stock offers potential upside, though investors should monitor execution risks and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
